Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News
  • Published:

US rejiggers Bioshield bill

Nature Biotechnology volume 22, page 792 (2004)Cite this article

In the weeks after 9/11 and during the anthrax attacks of 2001, administration officials and Congress promised pharma and biotech executives that the USgovernment would spare no expense and leave no obstacle in place to protect the nation against bioterrorism. In January 2003, Bush unveiled the biodefenses research and development program in his State of Union speech. The proposal didn't get very far in Congress, however, in part because it was long on hope but short on specifics.

Shortly after terrorist bombings in Madrid last March, however, the bill received a bit of tweaking. With the House promising swift passage of Bioshield, and Bush keen to sign the bill into law before elections this November, a goodly lot of government money should soon be flowing for biodefense-related diagnostics, vaccines and therapeutics development.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. New York

    Stephan Herrera

Authors
  1. Stephan Herrera
    View author publications

    Search author on:PubMed Google Scholar

Related links

Related links

Related links in Nature Research

Throwing money at biodefense

US budget/Bioshield initiative emphasizes bioterrorism countermeasures

US bioterrorism countermeasures research builds across a broad front

US budget emphasizes bioterrorism countermeasures

Related external links

“Bioshield enactment in sight”

Acambis

EluSys Therapeutics

National Venture Capital Association

Rights and permissions

Reprints and permissions

About this article

Cite this article

Herrera, S. US rejiggers Bioshield bill. Nat Biotechnol 22, 792 (2004). https://doi.org/10.1038/nbt0704-792

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nbt0704-792

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing